Rare disease definitions and orphan drug designation (ODD) requirements vary across jurisdictions, shaping development strategy and evidence needs. This article examines orphan drug designation frameworks in the US, EU, UK, Japan, and China, highlighting differences in eligibility criteria, timelines, and incentives. It discusses how these differences affect evidence generation, sequencing of submissions, and long-term global planning for orphan medicines.
